GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma
Abstract Background Cancer stem cells (CSCs) are implicated in carcinogenesis, cancer progression, and recurrence. Several biomarkers have been described for pancreatic ductal adenocarcinoma (PDAC) CSCs; however, their function and mechanism remain unclear. Method In this study, secretome analysis w...
Enregistré dans:
Auteurs principaux: | Jung Hyun Jo, Sun A Kim, Jeong Hoon Lee, Yu Rang Park, Chanyang Kim, Soo Been Park, Dawoon E. Jung, Hee Seung Lee, Moon Jae Chung, Si Young Song |
---|---|
Format: | article |
Langue: | EN |
Publié: |
BMC
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/eb3af251a62c4c54b9cc1856215d522c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma
par: Ricki T. Krog, et autres
Publié: (2021) -
Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance
par: Kostas Palamaris, et autres
Publié: (2021) -
TPH1 and 5-HT<sub>7</sub> Receptor Overexpression Leading to Gemcitabine-Resistance Requires Non-Canonical Permissive Action of EZH2 in Pancreatic Ductal Adenocarcinoma
par: Prakash Chaudhary, et autres
Publié: (2021) -
Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma
par: Sachie Kiryu, et autres
Publié: (2021) -
Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug
par: Emilia Alors-Perez, et autres
Publié: (2021)